Ranibizumab may prevent retinal detachment side effect

Proliferative vitreoretinopathy (PVR), or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. PVR is difficult to predict, lacks effective treatment options, and substantially reduces an individual's quality of life. Each year 55,000 people are at risk for developing PVR in the United States alone.

A new study carried out by scientists from The Schepens Eye Research Institute/Massachusetts Eye and Ear and the Department of Ophthalmology, Harvard Medical School, and published on The American Journal of Pathology website and scheduled for the May 2013 print edition, suggests that Ranibizumab, an anti-VEGF-A monoclonal antibody fragment, is a potential prophylaxis for PVR.

"In this manuscript we present basic studies that have clear implications for and therapy," said senior author Andrius Kazlauskas, Ph.D, Senior Scientist and Sinon Scholar in Retinal Research, Mass. Eye and Ear/Schepens Eye Research Institute and Professor of Ophthalmology, Harvard Medical School.

Researchers found that the putative mediators of PVR pathogenesis are growth factors, which contribute to such as atherosclerosis and cancer. "Consequently, elucidating functional relationships between growth factors and resolving their contribution to pathogenesis is of wide interest because such information will substantially advance our ability to combat a broad spectrum of diseases," Dr. Kazlauskas said.

While investigating the functional relationships between growth factors known to promote pervasive human diseases, researchers discovered that Ranibizumab reduced the bioactivity of vitreous from patients and experimental animals with PVR, and protected rabbits from developing this disease.

These pre-clinical findings suggest that one of the clinically approved approaches to neutralize VEGF-A constitutes a novel prophylactic for an incurable, blinding disease.

"Our discoveries also raise the provocative idea that anti-VEGF-based therapies may be effective for managing more than the angiogenesis- and vascular-permeability-driven pathological conditions," Dr. Kazlauskas continues.

More information: This study was funded by the NIH/National Eye Institute (EY022970), the Massachusetts Lions Foundation, the Department of Defense (WB1XWH-10-1-0392) and Canadian Institutes of Health Research (CIHR).

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Team creates device to alleviate dry eye

Jan 26, 2015

A search for medical needs in eye clinics led Stanford Biodesign fellows to develop an implantable neurostimulator that painlessly increases natural tear production.

Scientists discover gene tied to profound vision loss

Jan 16, 2015

An exhaustive hereditary analysis of a large Louisiana family with vision issues has uncovered a new gene tied to an incurable eye disorder called retinitis pigmentosa, according to an examination led by ...

Eye surgeon uses stem cells to repair damaged corneas

Jan 14, 2015

In Hyderabad, India, Sayan Basu is using stem cells in a pilot project to restore the eyesight of patients with damaged corneas. If proven successful, the procedure could mean that Indian citizens can avoid ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.